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Current treatment of Diabetic Kidney Disease and need for individualized approach 
Kidney disease is an ever-increasing problem worldwide in patients with diabetes. It 
affects one in three patients with type 2 diabetes, where type 2 diabetes affects 450 in 
2020 with projections for 2040 up to 642 million. (1) Diabetic kidney disease is 
associated with a high risk to end in chronic dialysis, transplantation or death, the former 
two placing a huge burden on individual patients lives as well as national healthcare 
budgets. (2,3) The international diabetes federation estimates that the costs of treating 
diabetes complications account for over 50% of the direct health costs, which are 
projected to reach USD 825 billion by 2030. Early detection of patients with type 2 
diabetes at risk for progression of kidney complications combined with effective 
individualized therapies are key steps to slow or even reverse disease progression.  
Landmark clinical trials have shown that optimizing glucose and blood pressure 
control can slow progression to end stage renal disease. The long-term follow-up of the 
ADVANCE trial demonstrated that intensive glucose lowering reduced the risk of 
doubling of serum creatinine or chronic dialysis by 65%. (4) The RENAAL and IDNT 
trials showed that specific blood pressure control using drugs intervening in the renin-
angiotensin-aldosterone-system (RAAS) such as angiotensin-receptor-blockers (ARBs) 
reduces the risk of chronic dialysis by approximately 25% in patients with diabetic kidney 
disease. Moreover, the IRMA-2 and INNOVATION trials showed that earlier 
intervention in the disease in patients with microalbuminuria progression to macro 
albuminuria, a hallmark in the progression of diabetic kidney disease, could be delayed. 
(5,6) However, despite the use of these interventions, there is still a high remaining or 
residual risk. The high residual risk is at least in part explained by the fact that not every 
patient responds optimally to intensive glucose or blood pressure control. In fact, an 
analysis of multiple studies has suggested that 30 to 40% of patients do not respond to 
ARBs. (7) These data suggest that an individualized approach optimizing lifestyle factors 
and pharmacotherapy for each individual according to the patient’s phenotype and 
environmental and social factors is required to improve long-term outcomes.  
Many clinical trials have been initiated over the past decades to evaluate new drugs to 
decrease the residual risk in patients with diabetic kidney disease. However, they still 
targeted the same drug at the same dose to a large population without taking into 
account how individual patients responded. The approaches consisted of enhanced 
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RAAS inhibition; dual blockade, targeting new risk markers, or the combination of 
treatments. However, none of these attempts were successful. Post-hoc analyses tried to 
find reasons for the failures, and suggested that subgroups of patients did benefit from 
these drugs, 
whereas other subgroups did not or were even harmed, so that the overall trial result was 
neutral or sometimes even indicating harm. Thus, to improve the outlook for individual 
patients a better understanding of the underlying factors involved in individual drug 
response and implementing strategies targeted to achieve optimal pharmacotherapy at an 
individual level are necessary.   
 
Determinants of individual drug response 
 Drug response variability can be a result of many factors. Previous studies have focused 
on individual's unique characteristics and aimed to improve phenotyping of individual 
patients to tailor new drugs to that specific patient. These efforts have led to new 
biomarkers that predict individual patient’s risk but few of these biomarkers are currently 
implemented in clinical practice and there remains a dearth of knowledge on which 
specific patient characteristics predict the individual’s response to a drug. It is also 
important to consider an individual’s personality, coping mechanisms, preferences, 
values, goals, health beliefs, social support network, financial resources, and unique life 
circumstances as these factors will also affect an individual’s health condition. In this 
respect, it is important to early engage patients and educate patients in order to advance 
personalized medicine. (8) 
 From a clinical pharmacological perspective, studying the exposure of an 
individual to a drug and associating the exposure to the pharmacodynamic response may 
provide further insight in underlying factors involved in the variability between 
individuals in drug response. So called exposure-response analyses are often performed 
at a population level when assessing the optimal dose of a drug. In such instances, the 
mean pharmacodynamics response is calculated for a given dose and different dose levels 
are correlated to different mean responses. In the area of diabetic kidney disease, 
however, there are very few studies that assessed the between patient variability in 
exposure to a drug and correlated the individual exposure of a drug to the individual 
pharmacodynamic response. In addition, many of the drugs used by patients with 
diabetic kidney disease are developed and registered as oral glucose, blood pressure or 
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cholesterol lowering drugs. The dose findings studies for these drugs are typically 
performed for these targets. However, many of the drugs also appear to exert effects on 
other cardiovascular or renal risk markers and these effects often contribute to the long-
term effect of the drug on cardiovascular or renal outcome. As an example, renin-
angiotensin-aldosterone-system inhibitors and sodium glucose co transporter 2 inhibitors 
do not only decrease blood pressure and blood glucose but also decrease UACR (and 
many other risk markers). (9) These so called off-target effects contribute to their long-
term kidney protective effects. However, individual exposure response relations for 
UACR and other off-target risk markers are unknown.  
 
Aim of the thesis:  
The overarching aim of this thesis was to determine to what extent the between-patient 
variability in drug exposure explains and contributes to the between-patient variability in 
pharmacodynamic drug response.  
 
In Chapter 2 we investigated the relationship between metformin exposure, renal 
clearance (CLr) and non-renal clearance of metformin (CLnr /F) in patients with type 2 
diabetes and varying degrees of kidney function. Metformin is cleared by the kidneys. 
When kidney function declines, the exposure of metformin increases. This can increase 
the risk of potentially fatal lactic acidosis. However, few studies have investigated the 
relationship between reduced kidney function, metformin exposure and lactic acidosis. 
We therefore conducted a prospective study to examine exposure of metformin. We 
demonstrated that when renal clearance decreases metformin exposure in terms of 
AUC0- τ increased proportionally whereas non-renal clearance did not change. These data 
indicated that it is possible to appropriately and safely treat patients with decreased renal 
function if the dose of metformin is appropriately adjusted. Based on these results we 
proposed a novel dosing algorithm that can be used to safely dose metformin in patients 
with various degrees of kidney function to maintain consistent drug exposure to assist in 
proper use of metformin in patients with diabetic kidney disease. 
 
In Chapter 3 we investigated the exposure-response relationship for the sodium glucose 
co-transporter 2 inhibitor dapagliflozin, taking into account multiple renal risk markers. 
Dapagliflozin has been shown to decrease various renal risk markers such as HbA1c, 
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systolic blood pressure, body weight and UACR in patients with type 2 diabetes and 
kidney disease. A prior study demonstrated that the response in these renal risk markers 
is variable between patients but reproducible upon re-exposure suggesting that the 
response to dapagliflozin is a true pharmacological response rather than a random 
response variation. Therefore, we examined the consistency in exposure and the 
correlation of exposure with response using data from the IMPROVE trial in which the 
same patient was exposed twice to dapagliflozin. (10) We demonstrated that there was a 
strong correlation between the measured plasma concentrations on two occasions 
supporting the notion that individual exposure is a true pharmacological phenomenon 
and not random.  We also demonstrated that higher exposure to dapagliflozin was 
associated with a larger reduction in renal and cardiovascular risk markers including urine 
albumin to creatinine ratio (UACR), body weight and acute reversible decrease in eGFR. 
Thus, we conclude that individual exposure to dapagliflozin is consistent upon re-
exposure and correlates with pharmacodynamics response in renal risk markers. In the 
IMPROVE study we unfortunately had only 
one blood sample available to assess exposure to dapagliflozin. Ideally, a full exposure 
profile is measured after drug administration to more precisely determine the individual’s 
exposure. We therefore initiated a prospective study to investigate exposure-response 
relationships for renal risk markers using an optimal pharmacokinetic sampling strategy 
for in the SGLT2-inhibitor empagliflozin, dipeptidyl peptidase 4 inhibitor linagliptin and 
angiotensin receptor blocker telmisartan.   
 
The results of this study are described in Chapter 4. Patients with type 2 diabetes and 
elevated albuminuria were enrolled in the study. In total, nine blood samples per patient 
over a 24 hours interval were taken at the first day of treatment. This allowed us to 
develop specific pharmacokinetic models for telmisartan, linagliptin and empagliflozin. 
The pharmacokinetic models allowed us to describe individual exposure expressed as 
AUC0-24. We observed a large variation in the pharmacokinetic profiles between subjects 
exposed to the same drug although they all received the same dose. Additionally, we 
observed a large inter-individual variation in response for various pharmacodynamic 
parameters including fasting plasma glucose, UACR response and systolic blood 
pressure. The individual exposures to the three drugs however did not correlate with 
responses in the tested renal risk markers, UACR, fasting plasma glucose and systolic 
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blood pressure. The lack of correlation between the individual exposure and 
pharmacodynamics response to the three drugs are not in keeping with the results 
observed in chapter 3. It is likely that the small sample size and associated low statistical 
power precluded us to detect an exposure response association in chapter 5. We 
therefore recommend large properly powered studies to confirm or refute our findings.  
 
In addition to blood glucose and blood pressure lowering drugs, cholesterol lowering 
drugs are also frequently used in patients with diabetic kidney disease to reduce 
cardiovascular risk. Statins also have multiple off-target effects including decreasing C 
reactive protein and UACR. The individual exposure response relationship to statins has 
not been investigated for their UACR lowering effect. We therefore investigated in 
Chapter 5 the exposure-response associations in atorvastatin and rosuvastatin.  
For this study we used data from the PLANET trials. The PLANET trials randomized 
patients with a urine-protein to creatinine ratio (UPCR) of 500-5000 mg/g and a fasting 
LDL-cholesterol >2.33 mmol/L to a 52-week treatment period with atorvastatin 80 mg, 
rosuvastatin 10 mg or rosuvastatin 40 mg. The trial program showed that atorvastatin 
but not rosuvastatin decreased urinary protein creatinine ratio (UPCR while LDL 
lowering effects of both statins were similar. However, the individual changes in both 
UPCR and LDL-cholesterol during treatments with these statins varied widely between 
patients and could not be explained by patients’ physical or biochemical characteristics. 
Therefore, we assessed whether the plasma concentrations of both statins were  
associated with LDL-cholesterol and UPCR response. We observed a large variation in 
plasma concentrations among individual patients, both for the different statins and dose 
groups. We also found a marked overlap in the plasma concentrations for patients 
receiving a 10 mg vs 40 mg dose. Plasma concentrations at week 52 were associated with 
LDL-cholesterol reductions but not with changes in UPCR.  
 
In summary, the studies described in this thesis demonstrated exposure-response 
associations for the on-target parameters of various drugs (i.e. blood pressure for an 
antihypertensive, LDL-cholesterol for a statin). However, exposure-responses 
associations for off-target parameters such as UACR were not consistent for all drugs 
and all studies. There are various potential explanations for this finding. First, the sample 
size of some studies was small thereby limiting statistical power. Secondly, in some 
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studies only though samples were available which may be insufficient to accurately reflect 
the overall 24-hr drug exposure of an individual.  Thirdly, drug concentrations were 
measured in the central blood compartment and we could not study the exposure 
response association in the target organ. It is possible that the blood concentration does 
not reflect the drug concentration in the vascular system or kidney which may explain 
the lack of exposure response association for UACR. The studies in this chapter thus 
provide an initial step towards understanding the individual drug exposure and 
pharmacodynamics response but additional studies are warranted.  




The above summary shows that if we want to succeed in reducing or resolving the unmet 
need in the treatment of progressive kidney disease in diabetes, we need to step away 
from looking at the mean response and start looking at individual response since in each 
study in this chapter we observed a large between-patient variation. To personalize 
medicine, various tools are nowadays available such as access to genotyping, predictive 
biomarkers, electronic health records coupled with machine learning tools and powerful 
bioinformatics computational techniques. If we leverage these tools in the right way it is 
possible to pave the way for a more individualized treatment approach. Variability in 
drug response is a multifactorial phenomenon caused by a complex interplay of 
environmental factors, drug factors and genetic make-up. With the results of the work in 
this thesis, I conclude that despite ongoing efforts we need to particularly focus in the 
future on pharmacokinetics, pharmacodynamics and novel trial design. 
The main focus in this thesis has been placed on the pharmacokinetic 
properties of the drugs by using population pharmacokinetic modeling techniques to 
describe individual drug exposure profiles and associate this with a pharmacodynamics 
response. We demonstrated that for renal risk markers, the exposure to the drug is in 
part associated with its effect. In current practice we attribute this often to dose, 
however, it is known that patients that use the same dose still have variation in response, 
and patients who are therapy resistant do not improve the response by increasing the 
dose. We need to appreciate and be aware that there is a great difference between dose 
and exposure. For atorvastatin and rosuvastatin, we have shown in this thesis that when 
administering a dose that is 4 times higher (40 mg vs 10 mg) a patient could still show 
the same exposure. Therefore, it is not dose but exposure that is expected to be related 
with drug response. Future studies should thus take into account the exposure more 
carefully. Single blood samples are not optimal to evaluate the exposure and I 
recommend that future studies develop sampling designs for multiple blood samples 
which provides more detailed information on the individual exposure but at the same 
should be operationally feasible and patient friendly. Moreover, while most studies, just 
like the studies described in this thesis, focus on the exposure measured in the central 
compartment, we need to advance current techniques to measure drug exposure in the 
target organs. Imaging techniques could help in this respect. For example, substituting 
certain atoms in a drug for PET radio-tracers allows imaging and quantification of drug 
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exposure in the target organs and will help to delineate determinants of individual 
response. Studies with for example 11C-telmisartan and 18F-canagliflozin are currently 
ongoing and are expected to provide new insights in the underlying mechanisms of drug 
response variability. 
A related field to be explored is the pharmacodynamic response. 
Pharmacometric techniques allow the integration of continuous outcome measurements 
into a model description. This is opposite of the current practice, where we tend to 
assess the pharmacodynamic response from a single start measurement to end 
measurement.  However, more granular assessments, insights in disease progression and 
trends in pharmacodynamic response will improve our knowledge and quantitative 
insights an individual’s response to drugs.  These systems pharmacology approaches are 
a promising future area. 
At the same time, individual patients would ultimately benefit from evaluating 
options for novel trial design to expedite the drug development process to get the right 
therapies to the right patients. Traditionally, a single pharmaceutical sponsor designs a 
single clinical trial for a single group of patients. However, new designs allow much 
faster and targeted studies to deliver a working drug for a responding group of patients. 
The ROTATE trial is an example of a trial that is designed to provide more information 
on individual responses to drugs. This trial randomized patients to treatment with four 
different drugs in random order (Telmisartan, Empagliflozin Linagliptin, and Baricitinib) 
and is designed specifically to provide insights in individual response mechanisms. Blood 
and urine samples are collected to phenotype each participant using various -omics 
platforms in order to develop specific patient profiles associated with a good or poor 
therapeutic response.  Establishing the individual drug response to four different drugs is 
unique and may pave the way for a more personalized therapy approach. This study will 
be completed in 2020 and the results will aid to develop specific strategies to overcome 
therapy resistance for individual patients.   
In conclusion, we need to integrate knowledge on individual drug response in 
the design of future clinical trials. A better understanding of the individual drug exposure 
and factors determining individual exposure is of importance to optimize design of 
clinical trials as well as individualizing and optimizing treatment strategies.  
 
